Browse News
Filter News
Found 808,840 articles
-
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
-
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
-
Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.
-
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
-
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.
-
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
-
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.
-
Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.
-
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
-
As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.
-
Pancreatic Cancer Market Size to Rise at USD 7.4 Billion by 2032
4/22/2024
The pancreatic cancer market size grew to USD 2.05 billion in 2022 and is estimated to hit approximately USD 7.4 billion by 2032, with a CAGR of 13.7% for the period of 2023 – 2032.
-
Primary Cell Culture Market Size to Worth Around USD 21.51 Billion by 2033
4/22/2024
According to Precedence Research, the primary cell culture market size was valued at USD 7.03 billion in 2023 and is expected to be worth around USD 21.51 billion by 2033, expanding at a CAGR of 11.81% from 2024 to 2033.
-
Single-cell Omics Market to Attain Valuation US$ 35.11 billion by 2033
4/22/2024
The global single-cell omics market size was evaluated at US$ 4.16 billion in 2023 and is expected to attain around US$ 35.11 billion by 2033, growing at a CAGR of 23.96% from 2024 to 2033.
-
High Potency Active Pharmaceutical Ingredients Market Size, Growth, Report 2024-2033
4/22/2024
According to Vision Research Reports, the global high potency active pharmaceutical ingredients market size was valued at USD 26.75 billion in 2023 and it is expected to surpass around USD 49 billion by 2033 with a CAGR of 6.24% from 2024 to 2033.
-
BoomRay's Radioactive Diagnostic New Drug [18F]BF3-BPA Injection Completes First Subject Enrollment in Phase I Clinical Trial
4/22/2024
BoomRay Pharmaceutical Co., Ltd. (“BoomRay”) announced that the phase I clinical trial of its positron emission tomography (PET) tracer [18F]BF3-BPA injection for the diagnosis of primary and metastatic brain tumors has completed the enrollment of the first subject.
-
Cell Therapy Market Size to Grow At 22.67% CAGR Till 2033
4/22/2024
The global cell therapy market size was valued at USD 4.85 billion in 2023 and is projected to surpass around USD 37.42 billion by 2033, registering a CAGR of 22.67% over the forecast period of 2024 to 2033 according to Nova One Advisor.
-
Single-cell Omics Market Size to Worth Around USD 9.65 Bn by 2033
4/22/2024
According to nova one advisor, the global single-cell omics market size was estimated at USD 2.15 billion in 2023 and is expected to be worth around USD 9.65 billion by 2033 with a CAGR of 16.2% from 2024 to 2033.
-
Synthetic Biology Industry is Rising Rapidly Up to USD 80.17 Bn by 2033
4/22/2024
The global synthetic biology market size was worth around USD 14.09 billion in 2024 and is predicted to grow around USD 80.17 billion by 2033 with a compound annual growth rate (CAGR) of roughly 18.99% between 2024 and 2033 According to a new report by Nova One Advisor.